Small Cap Feast

Small Cap Feast – 10 September 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp): 880

Total number of AIM Companies trading: 795*
* As at 09 September 2019

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): 88*

Total number of NEX Growth Market Companies trading: 86*
* As at 09 September 2019

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): 166*

Total number of Standard List Companies trading: 144*
* As at 09 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

Sanderson Group (SND) –    has been delisted from the AIM market due to a cash acquisition by Aptean Bidco. Aptean Bidco will acquire the entire issued and to be issued share capital of Sanderson for 140 pence in cash for each Scheme Share.

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

AIM

AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019

NEX

WORLD HIGH LIFE—The Investment Vehicle is to identify investment opportunities and acquisitions in legal Medicinal Cannabis, Hemp and CBD wellness sectors. The Company has raised £2,398,309 through three issues of Ordinary Shares to private subscribers

Breakfast Buffet

Immotion Group (IMMO) 6.90p £18.84m

Immotion Group, the UK-based immersive ‘Out of Home’ entertainment group, announced further development and roll out of its partnership model.

As stated at the time of the recent placing, the Company is now focused on the roll out of its partnership model into high footfall locations.  Trading in the current partner sites has been very encouraging over the summer months, with aquariums continuing to perform particularly strongly and overall there remains considerable interest from potential new partners as well as further developments with current partners.

Following early success at The 02, Immotion has agreed to extend the offering to include five additional headsets, taking the total number of headsets deployed to 17. The new addition will feature a five-person car racing set-up where users will be able to compete ‘head to head’ in the award winning ‘Project Cars 2’ game.

Mercia Asset Mgt (MERC) 31p £92.5m

Mercia Asset Management PLC, the proactive, regionally focused specialist asset manager, has completed a £2.0million direct investment as part of a £7.5million syndicated funding round into Birmingham-based software company Voxpopme Limited.

The investment round has attracted two new investors into the business, Chicago-based Origin Ventures and NVM Private Equity. Mercia’s direct equity stake is now 23.7%.

Voxpopme is a video insights platform that provides innovative video analytics for internationally renowned clients such as Microsoft, Airbnb, Coca-Cola, Verizon and Expedia. The business has already demonstrated rapid revenue growth operating in a market estimated to be worth c.$46billion in market research and c.$17billion in customer experience. Over the last 18 months Voxpopme has delivered strong revenue growth in both the US and Europe, with year-on-year annual recurring revenue growth exceeding 100%.

IQGeo Group (IQG) 42.5p £21m

IQGeo Group plc, a market leading provider of geospatial productivity and collaboration software for the telecommunications and utilities industries, announced that, since the trading update in July, it has continued gaining new customers and has recently been awarded a contract by a US based mid-sized telecommunications company worth a minimum of USD0.6m comprised of initial installation and configuration and a 3 year software subscription.

IQGeo successfully licensed its extended product set. The initial contract includes IQGeo’s software platform together with its Operations Manager and the recently launched Network Manager products, along with associated implementation services. IQGeo provides this new customer with an end-to-end, enterprise solution that includes the ability to design and roll out fiber networks, as well as monitor operations in real-time and deliver the technical and geospatial information needed by field engineers directly to their mobile devices.

Duke Royalty Limited (DUKE) 47.7p £94m

Duke Royalty Limited, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad, announced that it has entered into a new £30 million revolving facility agreement with its existing provider, Honeycomb Investment Trust PLC on improved terms.

The New Credit Facility replaces the previous £15 million facility agreement, assumed by Duke as part of its acquisition of Capital Step announced on 4 February 2019.  The increased facility will support Duke in delivering its growth strategy by providing access to additional capital, at a reasonable cost, without relying solely on equity markets. It is also expected to improve shareholder returns by minimising cash drag after equity placings.

Zinc Media Group (ZIN) 0.34p £4.4m

Zinc Media Group plc, the leading TV and multimedia content producer, announced new commissions, contributing to the current financial year totalling £4.8m, including three returning series, across its portfolio of TV companies. 

Reef TV, the Company’s London-based popular factual company, secured repeat commissions of two big series.  ‘[Police] Code Zero’, a docuseries exposing dangerous situations faced by UK police forces, is back in production for Channel 5 and ‘Critical Incident’, a series telling the stories of emergency service workers assaulted in the line of duty, will go into production for another series on BBC One.  These new commissions are significant for the Reef business, which struggled in FY18, and provides a strong platform for the new financial year.

Futura Medical (FUM) 43p £84m

Futura Medical, a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, announced a joint venture collaboration with CBDerma Technology Limited to explore the application of Futura’s advanced proprietary transdermal drug delivery technology, DermaSys® for delivery of Cannabidiol.  All Intellectual Property will be owned jointly by the Company and CBDerma Technology Limited.

CBDerma Technology is a company that has been established and funded to specifically exploit the therapeutic potential of Cannabis.

Angle (AGL) 70.5p £119m

ANGLE, a world-leading liquid biopsy company, is delighted to announce that Queen Mary University of London’s Barts Cancer Institute has published results of new work undertaken in early stage prostate cancer utilising ANGLE’s Parsortix® system demonstrating the potential to out-perform current standard of care in the detection and assessment of prostate cancer.  This builds on Barts Cancer Institute’s previous work with the Parsortix system in later stage prostate cancer and assessment of aggressiveness.

The work investigated 98 pre-biopsy patients and 155 newly diagnosed but as yet untreated prostate cancer patients over a two year period.

ULS Technology (ULS) 55p £35.35m

ULS Technology plc, the provider of online platforms for the UK conveyancing and financial intermediary markets, announces it has signed a Conveyancing Service agreement with Principality Building Society.

Principality Building Society is the 6th largest mutual building society in the UK, owned by and run for, the benefit of its 500,000 members. With a history spanning more than 150 years, Principality now has over £10 billion of customer assets. Principality arranges approximately 16,000 mortgages for customers per annum of which 6,000 are fees assist re-mortgages. Under this agreement, ULS has agreed to provide the Principality with the Company’s proprietary panel management and conveyancing technology platform, eConveyancer.

Omega Diagnostics (ODX) 11.5p £15m

Omega, the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has received a second purchase order from its new partner in China for 28,000 units of its 46-panel Food Detective® test (order value c. £400k). It is anticipated that this order will be supplied by early November 2019. This order is in addition to the first order for 20,000 units (order value c. £290k) announced on 16 August 2019 and supports our partner’s plan to commercialise early in 2020.

Ilika (IKA) 21.5p £22m

Ilika, a pioneer in solid-state battery technology and materials innovation, announces the offer of a further £0.9m funding directly to Ilika under the UK Government’s Faraday Battery Challenge: Innovation R&D, round three, for the ‘Granite project’, via the UK’s innovation agency, Innovate UK.

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.